These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12673114)

  • 21. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors in clinical development.
    Rosato RR; Grant S
    Expert Opin Investig Drugs; 2004 Jan; 13(1):21-38. PubMed ID: 14680450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
    Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
    Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
    Sato T; Suzuki M; Sato Y; Echigo S; Rikiishi H
    Int J Oncol; 2006 May; 28(5):1233-41. PubMed ID: 16596240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
    Yu C; Subler M; Rahmani M; Reese E; Krystal G; Conrad D; Dent P; Grant S
    Cancer Biol Ther; 2003; 2(5):544-51. PubMed ID: 14614324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors in programmed cell death and cancer therapy.
    Marks PA; Jiang X
    Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
    Marks PA; Richon VM; Rifkind RA
    J Natl Cancer Inst; 2000 Aug; 92(15):1210-6. PubMed ID: 10922406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
    Fantin VR; Richon VM
    Clin Cancer Res; 2007 Dec; 13(24):7237-42. PubMed ID: 18094401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.
    Kumar KS; Sonnemann J; Beck JF
    Oncol Rep; 2006 Nov; 16(5):1047-52. PubMed ID: 17016591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
    Blagosklonny MV; Robey R; Sackett DL; Du L; Traganos F; Darzynkiewicz Z; Fojo T; Bates SE
    Mol Cancer Ther; 2002 Sep; 1(11):937-41. PubMed ID: 12481415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
    Sonnemann J; Gänge J; Kumar KS; Müller C; Bader P; Beck JF
    Invest New Drugs; 2005 Mar; 23(2):99-109. PubMed ID: 15744585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors: insights into mechanisms of lethality.
    Rosato RR; Grant S
    Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.
    Moradei O; Vaisburg A; Martell RE
    Curr Top Med Chem; 2008; 8(10):841-58. PubMed ID: 18673170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.